KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Deferred Taxes: 2010-2024

Historic Deferred Taxes for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Dec 2024 value amounting to $56.1 million.

  • Biomarin Pharmaceutical's Deferred Taxes fell 212.11% to -$13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year increase of 912.86%. This contributed to the annual value of $56.1 million for FY2024, which is 224.71% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Deferred Taxes is $56.1 million, which was up 224.71% from -$45.0 million recorded in FY2023.
  • Biomarin Pharmaceutical's Deferred Taxes' 5-year high stood at $56.1 million during FY2024, with a 5-year trough of -$890.0 million in FY2020.
  • Its 3-year average for Deferred Taxes is -$13.7 million, with a median of -$45.0 million in 2023.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Deferred Taxes plummeted by 975.39% in 2020, and later skyrocketed by 224.71% in 2024.
  • Biomarin Pharmaceutical's Deferred Taxes (Yearly) stood at -$890.0 million in 2020, then spiked by 98.25% to -$15.6 million in 2021, then plummeted by 233.72% to -$52.1 million in 2022, then climbed by 13.64% to -$45.0 million in 2023, then surged by 224.71% to $56.1 million in 2024.